Rasagiline as Adjunct to Levodopa for Treatment of Parkinson’s Disease: A Systematic Review and Meta-Analysis

Figure 3

Forest plots and funnel plots for treatment effects of rasagiline/levodopa combination therapy versus levodopa monotherapy on (a) wearing-off time (hours), (b) levodopa dosage (mg/day), (c) UPDRS/MDS-UPDRS II score, (d) UPDRS/MDS-UPDRS III score, (e) PDQ-39 summary index score, and (f) incidence of TEAEs. CI, confidence interval; MDS-UPDRS, Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; PDQ-39, Parkinson’s Disease Questionnaire; RE, random effect; RR, risk ratio; SD, standard deviation; SMD, standardized mean difference; TEAE, treatment-emergent adverse event; UPDRS, Unified Parkinson’s Disease Rating Scale.

(a)

(b)

(c)

(d)

(e)

(f)